Repros Therapeutics Inc. (RPRX)

0.67
0.01 0.96
NASDAQ : Health Technology
Prev Close 0.68
Open 0.68
Day Low/High 0.67 / 0.68
52 Wk Low/High 0.26 / 1.33
Volume 251.77K
Avg Volume 732.30K
Exchange NASDAQ
Shares Outstanding 39.56M
Market Cap 26.51M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Repros Announces Negative Opinion From The EMA For Enclomiphene

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Repros Therapeutics Inc. In The Southern District Of Texas Houston Division
Lifshitz & Miller LLP Announces Investigation Of Almost Family, Inc., FNB Bancorp, Repros Therapeutics Inc., Snyder's-Lance, Inc., Southcross Energy Partners, L.P., Stone Energy Corporation And Tableau Software, Inc.

Lifshitz & Miller LLP Announces Investigation Of Almost Family, Inc., FNB Bancorp, Repros Therapeutics Inc., Snyder's-Lance, Inc., Southcross Energy Partners, L.P., Stone Energy Corporation And Tableau Software, Inc.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX

SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Repros Therapeutics, Inc. - RPRX

Repros Therapeutics Inc.® Receives Feedback Following An Oral Explanation With The European Medicines Agency

Repros Therapeutics Inc.® Receives Feedback Following An Oral Explanation With The European Medicines Agency

REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

REPROS THERAPEUTICS INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Rigrodsky & Long, P.A.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Repros Therapeutics Inc. To Allergan Plc Is Fair To Shareholders

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of An Investigation Concerning Whether The Sale Of Repros Therapeutics Inc. To Allergan Plc Is Fair To Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Repros Therapeutics Inc.

Repros Therapeutics Inc.® Announces Acquisition By Allergan Plc

Repros Therapeutics Inc.® Announces Acquisition By Allergan Plc

Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results

Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results

Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results

Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results

Repros Announces Proellex® Development Program Will Remain On Partial Clinical Hold By The FDA

Repros Announces Proellex® Development Program Will Remain On Partial Clinical Hold By The FDA

Repros Announces Pricing Of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results

Repros Announces The Issuance Of New U.S. Patent Relating To Treatment Using Off Drug Intervals For Certain Uterine Conditions

Repros Names Larry Dillaha, M.D., Its Permanent President And CEO

Company Holds Meeting With FDA To Discuss Oral Proellex® In The Treatment Of Uterine Fibroids

Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2016 Financial Results

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Repros Announces New CEO

Larry Dillaha, M.D., Named President and CEO on Interim Basis

FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids

FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism

FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism

Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids

Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids

Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities

Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities

FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism

Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism

Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis

Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis

Load More

From Our Partners

European advisory group backs seven medicines for approval, rejects Repros' enclomiphene
SeekingAlpha

Ad Com next week for Clarus Therapeutics' oral testosterone
SeekingAlpha

Prospects dim for European approval of Repros' enclomiphene for secondary hypogonadism; shares down 10% after hours
SeekingAlpha

Biotech Analysis Central Pharma News: AbbVie And Roche Stellar Data, Aduro Pulls The Cord, Allergan's Bargain Bin Buy
SeekingAlpha

Allergan Inks Deal to Buy Texas-Based Repros Therapeutics
Zacks

Your Daily Pharma Scoop: Omeros Potential, Portola's Setback, Proteostasis Soars
SeekingAlpha

Allergan to acquire Repros for $0.67 per share
SeekingAlpha

Repros Therapeutics reports Q3 results
SeekingAlpha

What's in the Cards for Repros (RPRX) This Earnings Season?
Zacks

Repros Therapeutics reports Q2 results
SeekingAlpha

Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
Zacks

Ladenburg terminates coverage of Repros Therapeutics
The Fly

Biotech Forum Daily Digest: Why Progenics Could Rally This Summer
SeekingAlpha

Repros' Proellex program to remain on partial clinical hold pending compilation of large safety database; shares slump 48% premarket
SeekingAlpha

Repros Therapeutics reports Q1 results
SeekingAlpha

Watchlist

Trending
A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)
15 Collectibles That Are Completely Worthless (Such as Your McDonald's Toys)
Will Tesla Stock Tumble 33% to $195?